Sacituzumab Tirumotecan
Drug timelines are a Plus or Pro feature.
30 regulatory and trial events tracked for Sacituzumab Tirumotecan, covering 2025-07-29 to 2026-06-09. Get the full timeline:
Most recent: Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) [Phase 3]